Published in Mol Cell on September 01, 2003
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev (2004) 3.28
APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol (2004) 3.17
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog (2006) 2.61
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol (2006) 2.58
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol (2005) 2.29
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature (2011) 2.26
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol (2005) 2.17
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol (2004) 1.97
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Early steps of retrovirus replicative cycle. Retrovirology (2004) 1.94
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93
Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx. J Virol (2009) 1.91
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol (2010) 1.85
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med (2006) 1.82
APOBEC3G targets specific virus species. J Virol (2004) 1.78
Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med (2006) 1.77
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol (2008) 1.74
The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol (2007) 1.74
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci U S A (2007) 1.73
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog (2007) 1.70
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70
FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics (2005) 1.70
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol (2006) 1.60
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol (2008) 1.57
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol (2007) 1.53
Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res (2006) 1.53
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology (2007) 1.52
Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol (2006) 1.52
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol (2007) 1.52
Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature (2014) 1.52
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology (2005) 1.51
Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology (2009) 1.50
Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem (2006) 1.50
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Species-specific restriction of apobec3-mediated hypermutation. J Virol (2007) 1.46
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog (2009) 1.45
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem (2010) 1.42
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One (2009) 1.37
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS One (2010) 1.28
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27
HIV vaccine research: the way forward. Science (2008) 3.86
NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol (2005) 3.50
Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell (2010) 3.42
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2013) 2.68
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol (2008) 2.38
Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol (2004) 2.06
p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem (2004) 2.01
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) (2003) 1.79
Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med (2006) 1.77
Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol (2007) 1.74
Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe (2011) 1.72
Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology (2010) 1.70
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70
In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog (2007) 1.70
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68
An integrated overview of HIV-1 latency. Cell (2013) 1.68
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47
Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem (2006) 1.42
Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J Virol (2011) 1.42
Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol (2005) 1.41
Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem (2009) 1.39
Slipping through the door: HIV entry into the nucleus. Microbes Infect (2002) 1.39
Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem (2004) 1.38
Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe (2008) 1.35
HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology (2004) 1.34
Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog (2011) 1.31
Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet (2011) 1.31
Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol (2004) 1.26
Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. PLoS Pathog (2013) 1.23
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23
Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol (2006) 1.22
NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol (2006) 1.20
The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog (2008) 1.18
Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem (2011) 1.18
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev (2012) 1.14
HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology (2002) 1.14
Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol (2005) 1.13
Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol (2006) 1.12
Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol (2003) 1.11
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem (2005) 1.10
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05
Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J Biol Chem (2003) 1.05
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Insights into the biology of HIV-1 viral protein R. DNA Cell Biol (2002) 1.02
Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J Virol (2003) 1.00
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99
Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol (2011) 0.99
HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology (2010) 0.99
Seminal plasma induces global transcriptomic changes associated with cell migration, proliferation and viability in endometrial epithelial cells and stromal fibroblasts. Hum Reprod (2014) 0.97
Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains. J Virol (2013) 0.96
NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS (2011) 0.95
Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology (2007) 0.94
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93
APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem (2005) 0.93
Assessing acetylation of NF-kappaB. Methods (2005) 0.92
A seminal finding for understanding HIV transmission. Cell (2007) 0.92
Host factors regulating post-integration latency of HIV. Trends Microbiol (2005) 0.90
Measuring HIV fusion mediated by envelopes from primary viral isolates. Methods (2010) 0.88
Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem (2010) 0.86
Protecting APOBEC3G: a potential new target for HIV drug discovery. Curr Opin Investig Drugs (2005) 0.85
Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol (2013) 0.84
Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. PLoS One (2013) 0.84
Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology (2009) 0.84
How resting T cells deMURR HIV infection. Nat Immunol (2004) 0.84
Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J Virol (2012) 0.79
APOBEC3G and HIV-1: strike and counterstrike. Curr HIV/AIDS Rep (2007) 0.79
[Role of semen-derived amyloid fibrils as facilitators of HIV infection]. Med Sci (Paris) (2012) 0.76
APOBEC3G and HIV-1: strike and counterstrike. Curr Infect Dis Rep (2006) 0.76
Corrigendum: Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature (2017) 0.75
Solutions to global health challenges: no more Band-Aids. J Clin Invest (2013) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Redistricting the retroviral restriction factors. Nat Med (2004) 0.75
Unsung hero Robert C. Gallo. Science (2009) 0.75